NCT05740722

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis: A Randomised Controlled Trial: The NORSEMAN Study

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Haukeland University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,

Detailed description

After being informed about the study and risks, all patients giving written informed consent will undergo a screening period to determine eligibility for study entry. At baseline patients who meet the eligibility requirements will be randomised in a double- blinded manner (patient and investigator) in a 1:1 ratio to nicotinamide riboside (1000 mg daily) or placebo (once a day)

Conditions

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Nicotinamid riboside	500 mg x 2 po
DIETARY_SUPPLEMENT	Placebo	Placebo tablets

Timeline

• Start date: 2023-05-03
• Primary completion: 2027-08-01
• Completion: 2027-12-30
• First posted: 2023-02-23
• Last updated: 2024-01-11

Locations

1 site across 1 country: Norway